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Abstract
MicroRNAs (miRNAs) are present in human plasma and known as a non-invasive biomarker for cancer detection. Our study
was designed to identify plasma miRNAs specific for rheumatoid arthritis (RA) by a comprehensive array approach. We
performed a systematic, array-based miRNA analysis on plasma samples from three RA patients and three healthy controls
(HCs). Plasma miRNAs with more than four times change or with significant (P,0.05) change in expression, or detectable
only in RA plasma, were confirmed with plasma from eight RA patients and eight HCs using real-time quantitative PCR.
Consistently detectable miRNAs that were significantly different between RA patients and HCs were chosen for further
validation with 102 RA patients and 104 HCs. The area under curves (AUC) were calculated after plotting the receiver
operating characteristic (ROC) curves. To determine if these miRNAs are specific for RA, the concentrations of these miRNAs
were analyzed in 24 patients with osteoarthritis (OA), and 11 patients with systemic lupus erythematosus (SLE). The array
analysis and the subsequent confirmation in larger patient cohort identified significant alterations in plasma levels of seven
miRNAs. The highest AUC was found for miR-125a-5p, followed in order by miR-24 and miR-26a. Multivariable logistic
regression analysis showed that miR-24, miR-30a-5p, and miR-125a-5p were crucial factors for making detection model of
RA and provided a formula for Estimated Probability of RA by plasma MiRNA (ePRAM), employing miR-24, miR-30a-5p and
miR-125a-5p, which showed increased diagnostic accuracy (AUC: 0.89). The level of miR-24, miR-125a-5p, and ePRAM in OA
and SLE patients were lower than that in RA. There was no significant difference in detection for anti-citrullinated protein
antibody (ACPA)-positive and ACPA-negative RA patients. These results suggest that the plasma concentrations of miR-24
and miR-125a-5p, and ePRAM are potential diagnostic markers of RA even if patients were ACPA-negative.
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Introduction
Rheumatoid arthritis (RA) is a systemic, chronic inflammatory
disease leading to joint destruction, deformity, and disability, with
heterogeneous manifestations [1]. Untreated patients have a
progressive course resulting in short- and long-term disability.
The number of effective medications for the treatment of RA has
rapidly expanded, and multiple studies have demonstrated that
aggressive treatment of early RA results in better clinical outcomes
than delayed therapy [2,3].
The American College of Rheumatology (ACR) and European
League Against Rheumatism (EULAR) developed new classifica-
tion criteria for RA in 2010 to recognize and treat the disease as
early as possible [4]. Although the main goal of the new criteria to
classify RA was to diagnose RA in an earlier phase, RA may be
falsely diagnosed in some patients with self-limiting disease [5].
When anti-citrullinated antibody (ACPA) and rheumatoid factor
(RF) are negative, more than 10 joints need to be affected to fulfill
the 2010 criteria of RA. Therefore biomarkers of a new category
for early disease diagnosis and for prediction of therapeutic
outcome, which enable clinicians to treat RA patients as early as
possible with the most optimal biologic therapy, are desired.
MicroRNAs (miRNAs) are endogenous small (approximately 22
nucleotides) noncoding RNAs that mediate mRNA cleavage,
translational repression or mRNA destabilization [6-8], and
currently more than 1000 human miRNAs are registered
(miRBase Release 18) [9]. miRNAs have been implicated in
important cellular processes such as lipid metabolism [10],
apoptosis [11], differentiation [12], organ development [13] and
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malignant tumors [14,15], and there is a prediction that one-third
of all mRNAs may be regulated by miRNAs [16].
Over the past several years, it has become clear that patients
with RA have alterations in their cellular miRNAs [17].
Dysregulation of miRNAs in peripheral blood mononuclear cells
[18], T lymphocytes [19], synovial fibroblasts [20–22] and
osteoclasts [23], each considered key effector cells in joint
destruction, was shown to contribute to inflammation, degradation
of extracellular matrix, and invasive behavior of resident cells.
Several years ago, miRNAs were shown to be present in human
plasma in a remarkably stable form, protected from endogenous
RNase activity [24]. Furthermore, miRNAs are present in
biological fluids such as semen, saliva, vaginal secretions,
menstrual blood and urine [25], and we demonstrated the
existence and stability of miRNAs in synovial fluid [26]. Such
miRNAs are diagnostic and prognostic biomarkers of various
cancers and tissue injuries [24,27,28].
We previously showed that miRNAs in plasma and synovial
fluid could be biomarkers for RA [26]. In that article, plasma miR-
132 of RA patients is lower than that of healthy controls (HCs) and
it was suggested to be diagnostic biomarkers for RA. However,
plasma miR-132 does not differentiate RA from osteoarthritis
(OA). To find out plasma miRNAs specific for RA, we took a
comprehensive array approach to plasma samples from patients
with RA and from HCs in this study. We identified novel miRNAs
associated with the presence of RA and validated with a large
number of plasma samples.
Materials and Methods
Ethics Statement
Ethical approval for this study was granted by the ethics
committee of Kyoto University Graduate School and Faculty of
Medicine. Informed consent was obtained from all study
participants.
Study Design and Participants
Identification of plasma miRNAs specific for RA was performed
in four phases (Figure 1). (1) Global plasma miRNA profiling
using TaqMan miRNA array cards (Life Technologies, Tokyo,
Japan): in this phase, plasma samples were collected from three
RA patients with high disease activity (28-joint Disease Activity
Score (DAS28) .4.1) and three age- and sex-matched HCs. (2)
Candidate miRNA selection: in this phase, plasma samples were
collected from eight patients with RA and eight HCs. (3)
Independent validation of candidate miRNAs and their evaluation
as potential biomarkers of RA: in this phase, samples from 102
patients with RA and 104 HCs were collected. Backgrounds of
participants are shown in Table 1. (4) Characterization of
candidate miRNAs: in this phase, candidate miRNAs were
quantified in plasma from 24 patients with OA and 11 patients
with systemic lupus erythematosus (SLE). Identification of
normalizer was performed as well (Figure 1). All of the patients
and HCs who contributed the plasma were Japanese.
RA, OA, and SLE were diagnosed according to the criteria of
the American College of Rheumatology [29–31]. HC plasmas
were collected from volunteers. By questionnaire, we confirmed
Figure 1. A flowchart illustrates how we analyzed plasma miRNAs. We performed a systematic, array-based miRNA analysis on plasma
samples from three rheumatoid arthritis (RA) patients and three healthy controls (HCs). Plasma miRNAs with more than four times change or with
significant (P,0.05) change in expression, or detectable only in RA plasma, were confirmed with plasma from eight RA patients and eight HCs using
real-time quantitative PCR (qRT-PCR). Eleven differently expressed miRNAs and one normalizer miRNA (miR-30a-5p) were chosen for further validation
with 102 RA patients and 104 HCs. The concentrations of two specific miRNAs and one normalizer miRNA were measured in 24 patients with
osteoarthritis (OA), and 11 patients with systemic lupus erythematosus (SLE). We also tried to find out miRNA that could be used for normalizer with
geNorm and NormFinder using the results of microarray. miR-30a-5p was a candidate normalizer.
doi:10.1371/journal.pone.0069118.g001
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that the volunteers were not being treated for arthralgia, heart
failure, renal failure, or autoimmune disease and free from other
inflammatory conditions.
Preparation of Blood Samples and Total RNA Isolation
Blood samples were collected with EDTA-2K containing tube
to separate plasma. Samples were centrifuged at 1400 g for 7 min
and stored at –80uC until analysis.
For miRNA arrays, plasma was thawed on ice and RNA was
isolated using RT2 qPCR-Grade miRNA isolation kit (SABios-
ciences, Frederick, MD) according to the manufacturer’s protocol.
The protocol was modified such that 4 ml of plasma was diluted
with 4 ml of RNase-free water, and extracted twice with Sepasol-
RNA II (Nacalai Tesque, Kyoto, Japan), a phenol-based reagent
for liquid sample. To normalize possible sample-to-sample
variation caused by RNA isolation, 1 pmol (total volume of
20 ml) of synthetic C. elegans miRNAs cel-miR-39 (Hokkaido
System Science, Sapporo, Japan), which has no homologous
sequences in humans, was added to each denatured sample.
Column was dried for 3 minutes after the last washing step before
elution.
For quantitative real-time PCR (qRT-PCR), total RNA was
extracted using a modified version of EXIQON’s protocol [32].
Briefly, plasma samples were thawed on ice and centrifuged at
3000 g for 5 min at 4uC to remove debris. Next, 150 ml of plasma
samples were mixed with 600 ml of TriPure Isolation Reagent
(Roche Applied Science, Mannheim, Germany) and 25 fmol (total
volume 5 ml) of synthetic cel-miR-39. Samples were vortexed,
incubated for 5 min at room temperature, mixed with 150 ml of
chloroform, shaked vigorously for 15 seconds, incubated for 3 min
and centrifuged at 12,000 g for 15 min at 4uC. The aqueous phase
(400 ml) was mixed with 600 ml of ethanol, and applied to RNeasy
Mini Spin Columns (Qiagen, Valencia, CA). Columns were
washed with 700 ml of Buffer RWT (Qiagen), three times with
500 ml of Buffer RPE (Qiagen), dried for 2 min, and eluted with
37.5 ml of DNase/RNase-free water.
Plasma miRNA Profiling and Data Analysis
For cDNA synthesis, 200 ng of total RNA was transcribed in a
7.5 ml volume with the TaqMan MicroRNA Reverse Transcrip-
tion Kit (Life Technologies) without pre-amplification according to
the manufacturer’s recommendations. qRT-PCR was performed
with the TaqMan human miRNA array pools A v3.0 and B v2.0
(Life Technologies) on an Applied BioSystems 7900 Real-Time
PCR system (Life Technologies). Data were automatically
analyzed with SDS Relative Quantification Software version
2.2.2 (Life Technologies). The GEO accession number for the
array data is GSE 46012. There is no current consensus of internal
control for plasma miRNA. Therefore, we used the average Ct
(threshold cycle) value of all miRNAs with valid amplification
plots. To validate the accuracy of the average Ct value as reference
and to find out the stably expressed candidate internal controls of
plasma miRNA, geNorm [33] and NormFinder [34] were used as
described before [35].
qRT-PCR of Mature miRNAs
Reverse transcription was performed using NCode VILO
miRNA cDNA Synthesis Kit (Life Technologies) according to
the manufacturer’s protocol. Using EXPRESS SYBR GreenER
qPCR SuperMix (Life Technologies), qRT-PCR was carried out
on an Applied BioSystems 7500 Thermocycler (Life Technologies)
according to manufacturer’s protocol. When we measured
absolute copy number, we performed qRT-PCR with standard
plasmids generated as described before [26] or synthetic first-
strand cDNAs with anticipated sequences. Details for quantifica-
tion and the way of designing the forward primers were described
before [26]. Primer sequences are available upon request. Data
were analyzed with SDS Relative Quantification Software version
2.06 (Life Technologies). The absolute concentration of miRNAs
in each sample was calculated as described before [26].
Statistical Analysis
Data are presented as the mean 6 standard deviation.
Statistical analyses were performed using JMP 8 (SAS Japan,
Tokyo, Japan). Student’s t test, chi-square test, Fisher’s exact test,
Pearson product-moment correlation coefficient, and logistic
regression analysis were used, as appropriate. A P value less than
0.05 was considered statistically significant.
Receiver operating characteristic (ROC) curve analyses, plot-
ting the true positive rate (sensitivity) vs. the false positive rate (1–
specificity) at various threshold settings [36], were performed for
plasma miRNAs, and the areas under curve (AUCs) were
calculated with JMP8. The maximum of the sum of true positive
rate and false positive rate were calculated, and cutoff value with
higher specificity was selected between the maximum and the
maximum minus 0.03.
For eight miRNAs measured in 102 patients with RA and
104 HCs, we derived likelihood ratio chi-squre and p value by
multivariable logistic regression analysis using JMP8. Using
miRNAs with p values less than 0.05, we calculated a risk
probability score, named ePRAM for ‘‘estimated Probability of
Table 1. Clinical details of the patients with rheumatoid
arthritis (RA) and healthy controls (HCs).
Characteristics RA HC
Number of patients 102 104
Sex, male/female 10/92 39/64
Age (y.o.) 63.6612.3 42.9612.3
Disease duration (y) 13.0610.2
Positive ACPA, n (%) 87 (85.2%) 1 (1.0%)
ESR (mm) 29.7626.4 NA
C-reactive protein (mg/l) 11.6617.3 NA
MMP3 (ng/ml) 1646140 NA
DAS28(CRP) 3.4261.07 NA
Remission (,2.3) 11 (10.8%)
Low Disease Activity (,2.7) 13 (12.7%)
Moderate Disease Activity (2.7–4.1) 47 (46.1%)
High Disease Activity (.4.1) 32 (31.4%)
Joint count for swelling 3.6164.47 NA
Joint count for tenderness 2.3962.87 NA
VAS (mm) 46.0624.3 NA




All values are reported as mean 6 standard deviation.
ACPA= anti-citrullinated protein antibody; ESR = erythrocyte sedimentation
ratio; MMP3= metalloproteinase-3, DAS28 = 28-joint Disease Activity Score,
VAS = visual analogue scale of general health, DMARDs =Disease Modifying
Anti-rheumatic Drugs, NA= not applicable.
doi:10.1371/journal.pone.0069118.t001
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RA by plasma MiRNAs’’, where ePRAM=exp(2x)/(1+exp(2x))
and x is linear expression of input microRNA concentrations.
Results
qRT-PCR Array Screening for miRNAs Associated with RA
An overview of the analysis of plasma miRNA described in this
manuscript is presented in Figure 1.
First we performed an analysis of plasma from three patients
with RA and three HCs, using a TaqMan miRNA array of 768
miRNAs (Figure 2A). Backgrounds of patients with RA and HCs
are shown in Figure 2B. To increase the likelihood of identifying
relevant candidate miRNAs, patients with high disease activity,
who had never received any biological therapy such as the anti-
TNF agents, were selected. As there is no current consensus of
appropriate reference RNA targets for the normalization of
plasma miRNA qRT-PCR analysis, we first tried to identify
normalizer miRNAs using geNorm and NormFinder. Candidate
normalizer miRNAs were those ubiquitously and highly expressed
(Ct value ,33) in most of the samples, thus limiting the choice to
miR-93-3p, miR-223-3p, miR-339-3p, miR-30a-5p, miR-301a-5p
and miR-484-5p (Figure S1A). As a result, the average Ct value
of all miRNAs was more appropriate reference for array analysis
than other candidate normalizer, and average Ct value was used
as internal control in this screening process. (Figure S1A).
As specific candidates, ten miRNAs (let-7e, miR-128, miR-323-
3p, miR-133b, miR-18b, miR-144, miR-451, miR-150, miR-486-
3p, and miR-196b-5p) were identified with a more than a four-fold
differential expression. Three miRNAs (miR-130b-5p, miR-452,
and miR-579) were detected only in plasma from RA patients, but
none were found only in plasma from HCs. In addition to these
miRNAs, seven miRNAs (miR-518d-5p, miR-202, miR-193b,
miR-26a, miR-30e-3p, miR-885-5p, and miR-374b) were signif-
icantly different (P,0.05) between RA patients and HCs
(Figure 2C).
To cover possible candidates of plasma miRNAs specific for
RA, we visually inspected the result of miRNA array and
additionally selected six miRNAs (miR-24, miR-28-5p, miR-28-
3p, miR-30c, miR-125a-5p, and miR-126-3p) according to the
following criteria. P values were between 0.05 and 0.1 (miR-24:
p = 0.06; miR-28-3p: p= 0.05); the average Ct values were less
than 30 with more than a two-fold differential expression (miR-28-
5p: fold change = 2.12; miR-125a-5p: fold change= 3.86); sub-
stantial expression differences were observed when the one outlier
sample was omitted (miR-30c and miR-126a-3p).
The miRNA array showed miR-16 and miR-223 fulfilled the
first criteria (p = 0.07 and 0.08, respectively), while amplification
plots of miR-132 were invalid. Although we previously showed
plasma miR-16, miR-132 and miR-223 are potential biomarkers
for RA, we did not add these miRNAs because they do not
differentiate RA from OA [26].
Figure 2. Plasma miRNA profiling using miRNA array. A: Microarray analysis for miRNA levels was performed with RNA isolated from the
plasma of three patients with rheumatoid arthritis (RA) and three healthy controls (HCs). The differences of the -DCt averages of each miRNA between
RA and HC are demonstrated in z axis. B: Background of the individuals who contributed the plasma samples. C: miRNAs with at least a four-fold
differential expression, with the expression only in RA, and with significantly different levels between RA patients and HCs (P,0.05).
PSL =prednisolone, MTX=methotrexate, MZR=mizoribine, mPSL=methylprednisolone, "=miRNAs listed in other categories, N.A. = not assessed.
doi:10.1371/journal.pone.0069118.g002
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The Concentrations of 11 Plasma miRNAs were Different
between eight RA Patients and Eight HCs
For the selection of biomarker miRNAs, plasma levels of 26
candidate miRNAs in eight RA patients and eight HCs (Table
S1) were assessed by qRT-PCR assays (Figure 3). Spike-in cel-
miR-39 was used for normalization in this phase.
The levels of 11 miRNAs (miR-24, miR-26a, miR-28-5p, miR-
28-3p, miR-30c, miR-30e-3p, miR-125a-5p, miR-126-3p, miR-
130b-5p, mR-133b and miR-202) were significantly different
between RA patients and HCs (Figure 3), and interestingly, in all
cases the levels of these miRNAs were elevated in RA plasma
relative to HC plasma. We could not detect miRNAs that were
found exclusively in RA or HC plasma.
Identification of Normalizer in Plasma Samples between
RA and HC
In the microarray analysis, geNorm and NormFinder showed
miR-93-3p, miR-223-3p, miR-339-3p, miR-30a-5p, miR-301a-5p
and miR-484-5p were the candidate normalizer (Figure S1A).
We verified whether miR-93-3p, miR-223-3p, miR-339-3p,
miR-30a-5p, miR-301a-5p and miR-484-5p could work as
normalizer in NCode qRT-PCR, using samples from RA patients
and HCs (n= 48, respectively). miR-93-3p, miR-223-3p, and miR-
339-3p were delisted because of their high Ct values (Figure
S1B). miR-484-5p was also excluded from the candidate
normalizer because of low specificity of primers. miR-24 is
demonstrated as a representative miRNA showing different
expression between RA patients and HCs in Figure S1B.
The standard deviation of Ct value of spike-in cel-miR-39 was
less than one cycle (Figure S1C) while standard deviations of
miR-30a-5p and miR-301a-5p were 1.12 and 1.36 respectively.
Consistent with this result, screening using spike-in cel-miR-39 for
normalizer detected more candidate miRNAs for diagnostic
biomarker than those using miR-30a-5p or miR-301a-5p (Figure
S1D) and in larger cohort analysis (data not shown). These results
indicate that cel-miR-39 is the best normalizer for the screening of
candidate plasma miRNAs and that miR-30a-5p is the second best
normalizer.
Plasma miR-24, miR-26a and miR-125a-5p Differentiated
RA from HC with High Specificity
To verify whether candidate 11 miRNAs (miR-24, miR-26a,
miR-28-5p, miR-28-3p, miR-30c, miR-30e-3p, miR-125a-5p,
miR-126-3p, miR-130b-5p, mR-133b and miR-202) in Figure 3
could discriminate RA patients from HCs, we measured the
absolute concentration of these plasma miRNAs in 102 patients
with RA and 104 HCs (Figure 4A). Backgrounds of participants
are shown in Table 1. miR-130b-5p, miR-133b and miR-202
were delisted because of high Ct values and/or poor degenerating
curve (data not shown). The concentration of miR-30a-5p was also
quantified as the second best normalizer.
The highest AUC was found for miR-125a-5p, followed in
order by miR-24 and miR-26a (Figure 4A, 4B). ROC analysis
revealed that at a cutoff value of 1.46 pM for miR-24, the
sensitivity was 63.7% and the specificity was 89.5% (Figure 4C,
4D). At a cutoff value of 3.09 pM for miR-26a, the values were
53.9% and 94.3%, respectively, and a cutoff value of 8.17610–
2 pM for miR-125a-5p, the values were 64.7% and 89.5%,
respectively.
These results suggest that plasma miR-24, miR-26a and miR-
125a-5p can be diagnostic biomarkers with high specificity.
Figure 3. The concentrations of 11 plasma miRNAs were different between eight RA patients and eight HCs. Plasma concentrations of
26 miRNAs were compared in RA patients and HCs (n = 8, respectively) by qRT-PCR assays. In addition to twenty miRNAs showed in Figure 2C, we
measured the concentration of six miRNAs (miR-24, miR-28-5p, miR-28-3p, miR-30c, miR-125a-5p, and miR-126-3p) selected by manual inspection
according to the process described in the main text. * = P,0.05, ** = P,0.01.
doi:10.1371/journal.pone.0069118.g003
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Combination of miRNAs Increased Diagnostic Accuracy
In general, the specificity of biomarkers based on a single
miRNA is relatively low [37], because many different genes in
multiple cell types contribute to disease pathology, in addition to
the heterogeneity of the disease, and the combinations of several
miRNAs had been also analyzed [38,39].
We conducted multivariable logistic regression analysis using
seven miRNAs with significant difference (miR-24, miR-26a, miR-
28-5p, miR-28-3p, miR-30c, miR-125a-5p, and miR-126-3p) and
one normalizer miRNA (miR-30a-5p). The likelihood ratio test
revealed that miR-24, miR-30a-5p, and miR-125a-5p were crucial
factors for making detection model of RA by multivariate logistic
regression analysis (Figure 5A), and the combination of miR-24,
miR-30a-5p, and miR-125a-5p (termed ePRAM for ‘‘estimated
Probability of RA by plasma MiRNAs’’) was a potential biomarker
for diagnosis of RA (Figure 5B, 5C, 5D), while adding miR-26a
to the combination did not improve the diagnosis ratio of RA,
suggesting an overlapping component of miR-26a with miR-24,
miR-30a-5p, and miR-125a-5p in terms of diagnostic value.
Moreover, miR-26a had been demonstrated to be dysregulated in
plasma from patients with other diseases including prostate cancer,
intracerebral hemorrhage, and preeclamptic pregnancies [40–42],
suggesting that plasma miR-26a is not a specific biomarker for RA.
ePRAM showed, at a cutoff value of 0.50, the sensitivity was
78.4% and the specificity was 92.3% with an AUC of 0.89,
indicating combination of miRNAs increased diagnostic accuracy.
Correlation of Candidate miRNAs with Clinical Variables
To assess the potential of candidate miRNAs as biomarkers of
RA, and to determine whether the increased plasma levels in RA
patients reflect only the general inflammation, we examined
correlation coefficients between miRNAs and established clinical
variables, including RF, ACPA, serum matrix metalloproteinase-3
(MMP-3), C-reactive protein (CRP), erythrocyte sedimentation
rate (ESR), DAS28, swollen joint count (SJC), and tender joint
count (TJC).
Plasma miR-125a-5p did not correlate with ESR, CRP, RF,
ACPA, or DAS28, indicating that the change in plasma miR-
125a-5p is not a mere reflection of general inflammation and is
insulated from the influence of disease activity of RA as is the case
with ACPA (Table S2). Plasma miR-24 had a correlation with
CRP, VAS, DAS28(ESR) and DAS28(CRP), and ePRAM had
with DAS28(ESR) and DAS28(CRP). However plasma miR-24
and ePRAM in OA or SLE were significantly lower than those in
RA. These results indicate that plasma miR-24 and ePRAM can
be markers for disease activity of RA and for differentiation of RA.
Evaluation of Candidate miRNAs as Potential Biomarkers
First, cutoff values for miRNAs as RA markers were validated
with samples from patients with OA, as noninflammatory arthritis,
and SLE as non-RA systemic autoimmune disease. Backgrounds
of participants are shown in Figure 6A. The level of plasma miR-
24, miR-125a, and ePRAM in patients with OA or SLE was lower
than that in RA (P values for OA: 4.5610224, 3.2610215, and
5.461029; for SLE: 0.01, 0.1, and 0.01, respectively). In patients
with OA, the percentage of true negative for miR-24, miR-125a-
Figure 4. Plasma miR-24, miR-26a and miR-125a-5p differentiated RA from HC with high specificity. A: Plasma concentrations of eight
miRNAs for candidate biomarker and miR-30a-5p for candidate normalizer in RA patients (n = 102) and HC (n= 104). Data are shown as mean 6
standard deviation. Area under curve (AUC) was calculated after plotting receiver operating characteristic (ROC) curve. B: ROC curve analyses of miR-
24 (left panel), miR-26a (middle panel) and miR-125a-5p (right panel), which showed the highest values for AUC. C: Histograms of plasma
concentrations of miR-24 (left panel), miR-26a (middle panel), and miR-125a-5p (right panel). The green panels indicate the cutoff value. D: Sensitivity
and specificity of each miRNA test for RA. Cutoff value with higher specificity was selected between the maximum and the maximumminus 0.03 after
the maximum of the sum of true positive rate and false positive rate were calculated.
doi:10.1371/journal.pone.0069118.g004
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5p, and the ePRAM test was 79%, 79%, and 75%, respectively
(Figure 6B). In patients with SLE, 91%, 64%, and 64% were
diagnosed negative for RA (Figure 6B). These results suggest that
the plasma level of these miRNAs is not likely to be influenced by
cartilage destruction or general systemic autoimmunity and that
miR-24, miR-125a-5p, and ePRAM could be disease-specific
makers for RA.
Next, we analyzed diagnostic accuracy for ACPA-negative RA
patients, because ACPA-negative patients are difficult to be
diagnosed as RA. Analyses for miR-24, miR-125a-5p, and
ePRAM were positive in 47%, 67%, and 73% of ACPA-negative
patients (n = 15), respectively (Figure 6C, 6D). There was no
statistically significant difference in the sensitivity of detection for
ACPA-positive and ACPA-negative RA patients.
The level of miR-125a-5p had a weak negative correlation with
age (r = –0.25, P,0.05), while miR-125a-5p concentrations of RA
patients in their 309s and 509s were still higher than those of HCs
(Figure S2A). With respect to miR-24, there was no significant
correlation between the plasma level and age (data not shown),
and plasma level of RA patients was significantly higher than that
of HCs in each age-group (Figure S2A). Furthermore the
difference of ePRAM between age-groups was little. These
collectively indicate that plasma level of miR-24 and miR-125a-
5p are certainly affected by RA, and that age-related change of
miR-125a-5p is able to be corrected by combination of miRNAs
(ePRAM).
Finally, we analyzed the effects of treatment modalities on
positivity of each miRNA test by multivariable logistic regression
analysis (Figure S2B). Plasma miR-24, miR-125a-5p, and
ePRAM had no correlation with treatment modalities.
Discussion
Recently miRNAs have emerged as potential new blood-based
markers for the detection of cancers and other diseases. Despite
the RNase-rich environment of blood, circulating miRNAs show
remarkable stability after prolonged incubation at room temper-
ature and/or multiple freezing-thaw cycles. Furthermore, the
characteristics of miRNAs, such as tissue specificity would indicate
potential advantages as a biomarker, and increasing number of
studies have demonstrated the potential use of circulating miRNA
in serum/plasma as biomarker for various malignancies
[5,27,28,38,43,44], tissue injuries [45], sepsis [46], and pregnancy
[47,48]. In addition, circulating miRNAs have shown potential as
biomarkers for chemo-resistant cancers [49,50], which is impor-
tant for deciding treatment strategies.
However, the possible functions and protective mechanisms of
circulating miRNAs remain unclear. A recent study has revealed
that the majority of circulating miRNAs co-fractionated with Ago2
protein complexes to avoid RNase digestion [51]. The existence of
extracellular Ago2-miRNA complexes in plasma raises the
possibility that cells release a functional miRNA-induced silencing
complex into the circulation. Other investigators in circulating
miRNA research have also agreed that miRNAs can be secreted
via cell-derived microvesicles, including microparticles and exo-
somes, and can transfer the gene-silencing signal between living
cells in vitro and in vivo [52,53]. Moreover, miRNAs have shown
to be also transported to blood by high-density lipoproteins (HDL)
[54]. HDL was also demonstrated to deliver miRNAs maintaining
their functional capabilities to recipient cells.
To the best of our knowledge, miR-24 and miR-125a-5p were
shown to be associated with the disease for the first time, while
miR-26a has been demonstrated to be dysregulated in plasma
from patients with prostate cancer, intracerebral hemorrhage, and
preeclamptic pregnancies [40–42]. Multivariate logistic regression
analyses and likelihood ratio test revealed that the combination of
miR-24 and miR-125a-5p increased a likelihood of a diagnosis of
RA (Figure 5A, 5B), while adding miR-26a to the combination of
miR-24 and miR-125a-5p did not increase the risk of RA (data not
shown), which supports a less significant diagnostic value of miR-
26a. The level of plasma miR-26a might be dysregulated in
response to the cell stresses such as acute and/or chronic
inflammation.
In contrast, plasma miR-125a-5p did not significantly correlate
with any evaluated clinical parameter. Plasma miR-24 and
ePRAM correlated with disease activity of RA and the level of
miR-24, miR-125a-5p, and ePRAM in OA and SLE was lower
than that in RA. These results suggest that plasma miR-24 and
Figure 5. Combination of miR-24, miR-30a-5p, and miR-125a-
5p increased diagnostic accuracy. A: Likelihood ratio test to
identify miRNAs which would be crucial for making detection model of
RA by multivariable logistic regression analysis. Addition of miR-26a to
the combination did not improve the diagnosis ratio of RA. B: ROC
analysis of the combination of miR-24, miR-30a-5p, and miR-125a-5p
(ePRAM, estimated probability for RA by plasma miRNAs). C: Histogram
of ePRAM. The green panel indicates the cutoff value. D: Sensitivity and
specificity of ePRAM.
doi:10.1371/journal.pone.0069118.g005
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miR-125a-5p, and ePRAM are not likely to be altered just in
response to general inflammation alone.
Aging significantly decreased plasma miR-125a-5p level.
However in each age-group miR-125a-5p was still able to
differentiate RA patients and HCs (Figure S2A). In future study,
we will be able to find age-appropriate threshold and new
relevance between aging and plasma miRNAs.
Although further determination is required, one supposed role
of miR-24 and miR-125a-5p might be an enhancement of the
inflammation. miR-24 regulates the processing of latent trans-
forming growth factor, beta 1 (TGF-b1) through direct targeting of
Furin [55] and miR-125a-5p targets the tumor necrosis factor
alpha-induced protein 3 (TNFAIP3) [56]. TGF-b1 has a
suppressive role in controlling the immune system [57], and the
expression of Furin in T-cells is required for maintenance of
peripheral immune tolerance [58]. The TNFAIP3 locus is
implicated as a positively associated factor in RA [59] and
knockout of TNFAIP3 in mice triggered erosive polyarthritis
resembling RA [60]. Downregulation of TGF-b1, Furin, and
TNFAIP3 by miR-24 and miR-125a-5p may deteriorate the
arthritis.
ePRAM in this study includes miR-30a-5p, in addition to miR-
24 and miR-125a-5p. In calculating ePRAM, miR-30a-5p carried
out subtraction with other miRNAs (Figure 5). Because the level
of miR-30a-5p was one of the most consistent miRNAs across
samples in the miRNA microarray (Figure S1), it might have a
role in reduction of measurement deviation.
Other studies showed the significant difference between SLE
and HC in plasma concentration of miR-16, miR-21, miR-125a-
3p, miR-126-5p, miR-146a, miR-155, miR-223, miR-451 and the
combination of miR-17, miR-20a, miR-106a and miR-142-3p
[39,61]. However their resulted failed to show these miRNAs were
specific for RA. In their studies, there were no differences in the
concentrations of miR-17, miR-20a and miR-106a in the miRNA
array. There were less than two-fold differences between RA and
HC in plasma miR-16, miR-21, miR-126-5p, mR-155 and miR-
223 with our miRNA array. Regarding miR-125a-3p, miR-142-
3p, and miR-146a, there were no amplifications in two or more
samples. The concentration of miR-451 showed no significant
difference between eight patients with RA and eight HCs in this
study.
It is noteworthy that high levels of sensitivity and specificity for
RA were obtained on analysis of plasma miR-24, plasma miR-
125a-5p and the ePRAM test. This was the result despite relatively
tight clinical control of RA activity. In this study, about 23% of
patients were in a state of low disease activity or remission, and
15% of patients were being treated with biologics. In addition,
67% and 73% of ACPA-negative patients were positive for the
miR-125a-5p and ePRAM tests, respectively. Since patients
negative for ACPA and RF need to wait until more than 10
joints are affected to start treatments according to the definite
diagnosis of RA, these findings suggest that miR-24, miR-125a-5p
and ePRAM are promising diagnostic markers of RA.
Some limitations of the present work need to be acknowledged.
In the first screening, we compared three RA patients and controls
using miRNA array. Because outliers or poor amplification were
occasionally present in data, we couldn’t help using manual
inspection to pick up possible candidate miRNAs. Furthermore,
we needed to manually exclude miRNAs which showed poor
amplification curves in the array and qRT-PCR. In the second
candidate miRNA selection using eight samples in each group, we
delisted apparently unspecific miRNAs from the candidates for the
final validation. Although there is a possibility that some delisted
miRNAs might be differently expressed in the final large cohort,
we identified seven miRNAs including miR-24 and miR-125a-5p
as biomarkers specific for RA.
Inconsistencies across the studies about circulating miRNAs in
breast cancer detection were indicated [62]. Reproducibility
experiment is required using other cohort and modalities including
next generation miRNA sequencing. The control groups of this
study are currently limited to SLE and OA patients and HCs, so it
will be necessary to verify the specificity of our proposed
Figure 6. Evaluation of candidate miRNAs. A: Clinical features of patients with OA and SLE who contributed plasma. B: Plasma concentrations
of miR-24, miR-125a-5p, and ePRAM in patients with osteoarthritis (OA) and systemic lupus arthritis (SLE). The green areas indicate the ranges in
which patients are diagnosed as RA positive. C: Histogram of plasma concentrations of each miRNA in anti-citrullinated protein antibody (ACPA)-
negative RA patients, ACPA-positive RA patients, and HCs. The green panels indicate the cutoff value. D: Sensitivity of each miRNA test in ACPA-
positive and ACPA-negative RA patients. Data are shown as mean 6 standard deviation. SLEDAI = SLE Disease Activity Index.
doi:10.1371/journal.pone.0069118.g006
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biomarkers by analyzing plasma from patients with infection,
injury, crystal-induced arthropathy, and other inflammatory
conditions. The diurnal and longer-term variation in concentra-
tions of each miRNA in individual patients has not been
investigated.
Since we analyzed plasma from patients with established RA in
a cross-sectional manner, it is not clear whether miR-24, miR-
125a-5p and ePRAM can be biomarkers for at-risk patients, the
prediction of RA prognosis, or the prediction of the therapeutic
outcome. Further studies regarding these issues are required.
Identification of the mechanism and source of extra-cellular miR-
24 and miR-125a-5p will also clarify the role of miR-24 and miR-
125a-5p as biomarkers.
In conclusion, using a comprehensive array approach to plasma
from RA patients, we have identified an increase in the
concentration of miR-24, and miR-125a-5p as potential diagnostic
markers of RA.
Supporting Information
Figure S1 Identification of normalizer candidates of plasma
miRNAs. A: geNorm and NormFinder analysis of Taqman
miRNA array data revealed miR-93-3p, miR-223-3p, miR-339-
3p, miR-30a-5p, miR-301a-5p, and miR-484-5p as candidate
normalizer of plasma miRNAs. Average represents average cycle
threshold (Ct) values and shows lowest M value and Stability
Value, indicating most appropriate reference for array analysis. B
and C: Using samples from rheumatoid arthritis (RA) and healthy
controls (HCs) (n = 48, respectively), each miRNAs were quanti-
fied by NCode quantitative real-time PCR and the average Ct
values (B) and standard deviation (C) of all samples were shown.
miR-24 is demonstrated as a representative miRNA with different
expression between RA patients and HCs. D: The number of
miRNAs with significantly different expression between RA and
HC (n=8, respectively) among 26 miRNAs selected by miRNA
array analysis with normalization to cel-miR-39, miR-30a-5p and
miR-301a-5p. N.D. = not detectable
(TIF)
Figure S2 Influence of patient background on miRNA concen-
trations. A: The concentrations of miRNAs were shown every 10
years old. Five RA patients and 21 HCs were in their thirties.
Eleven RA patients and 32 HCs, 17 RA patients and 24 HCs
were in their forties and fifties, respectively. Data are shown as
mean and standard deviation. B: The influence of the drug use on
each miRNA test positivity was analyzed by multivariable logistic
regression analysis. * = P,0.05, ** = P,0.01. N.S. = not signifi-
cant, MTX=methotrexate; NSAIDs=non-steroidal anti-inflam-
matory drugs.
(TIF)
Table S1 Background of patients with rheumatoid arthritis (RA)
and healthy controls (HCs).
(DOCX)
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